Autolus Therapeutics plc (NASDAQ: AUTL) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $10.00 price target on the stock.
Autolus Therapeutics price target lowered to $10 from $11 at Truist [Yahoo! Finance]
Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
Autolus Therapeutics plc (NASDAQ: AUTL) had its price target lowered by analysts at Truist Financial Co. from $11.00 to $10.00. They now have a "buy" rating on the stock.
Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025